Yushi Feng
About Yushi Feng
Yushi Feng: Vice President of Regulatory Affairs at Capricor
Yushi Feng joined Capricor in 2023 as the Vice President of Regulatory Affairs. With an extensive 17-year background in regulatory affairs, both from the industry and the FDA, Feng brings a wealth of expertise to the company. His current focus areas include oncology, neurology, rare diseases, and infectious diseases.
Regulatory Experience and FDA Background of Yushi Feng
Yushi Feng has over 17 years of experience in regulatory affairs. His career includes significant roles in both the industry and the FDA. At the FDA, he served as a chemistry reviewer for infectious diseases, ophthalmology, and transplant. His industry expertise spans manufacturing, quality systems, and regulatory submissions.
Key Roles in Exosome-Based Therapeutics and Oligonucleotide Research
Prior to joining Capricor, Yushi Feng held the position of Vice President of Regulatory Affairs at Codiak BioSciences, where he shepherded multiple successful industry-first regulatory filings on exosome-based therapeutics in the U.S. and United Kingdom. At Wave Life Sciences, he contributed to advancing the use of oligonucleotides for treating rare neurodegenerative diseases such as Duchenne muscular dystrophy and Huntington’s disease.
Educational Background of Yushi Feng
Yushi Feng earned his Ph.D. in Pharmaceutics from the University of Minnesota. Prior to that, he completed his undergraduate studies at Ocean University of China. His educational foundation has significantly contributed to his expertise in the field of regulatory affairs.
Analytical and Formulation Development Experience
In addition to his regulatory roles, Yushi Feng has explored the functions of formulation and analytical development at Eli Lilly Company and Vertex Pharmaceuticals. His extensive experience in these areas has equipped him with a comprehensive understanding of the pharmaceutical industry.